Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Calcium; Vitamin D
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Sponsors Shanghai Biomabs Pharmaceuticals

Most Recent Events

25 Mar 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
25 Mar 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
26 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight